Technical Analysis for SMMT - Summit Therapeutics plc

Grade Last Price % Change Price Change
grade F 1.71 6.21% 0.10
SMMT closed up 6.21 percent on Monday, May 20, 2019, on 40 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical SMMT trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
180 Bearish Setup Bearish Swing Setup 6.21%
Inside Day Range Contraction 6.21%
Down 3 Days in a Row Weakness 6.88%
Lower Bollinger Band Touch Weakness 6.88%
200 DMA Resistance Bearish -3.39%
Doji - Bullish? Reversal -3.39%
Outside Day Range Expansion -3.39%
Narrow Range Bar Range Contraction -3.39%
NR7 Range Contraction -3.39%

Older signals for SMMT ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Summit Corporation plc, a drug discovery and development company, engages in the discovery and development of novel drug candidates to treat areas of high unmet medical need. The company licenses its drug discovery platform, known as Seglin technology, for the identification of new drug leads and candidates with the potential to target a range of diseases. Its pipeline consists of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infection (CDI). The company provides SMT C1100, a small molecule Utrophin modulator for DMD patients that has completed Phase I clinical trial; and SMT 19969, a Phase I clinical trial completed novel molecule antibiotic for the treatment for initial CDI and prevention of recurrent disease. It is also engaged in other programmes that include OGA inhibitor programme for the treatment of dementia. The company has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology platform. It has operations primarily in the United Kingdom and the United States. The company was formerly known as VASTox plc and changed its name to Summit Corporation Plc in July 2007. Summit Corporation plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.
Medicine Medical Specialties Diseases Drug Discovery Dementia Muscular Dystrophy Duchenne Muscular Dystrophy Clostridioides Difficile Clostridium Difficile Infection
Is SMMT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 14.12
52 Week Low 1.1
Average Volume 26,071
200-Day Moving Average 1.7735
50-Day Moving Average 1.8552
20-Day Moving Average 1.768
10-Day Moving Average 1.718
Average True Range 0.1103
ADX 23.07
+DI 11.6439
-DI 20.683
Chandelier Exit (Long, 3 ATRs ) 1.6891
Chandelier Exit (Short, 3 ATRs ) 1.8809
Upper Bollinger Band 1.9695
Lower Bollinger Band 1.5665
Percent B (%b) 0.36
BandWidth 22.794118
MACD Line -0.0537
MACD Signal Line -0.0447
MACD Histogram -0.009
Fundamentals Value
Market Cap 21.18 Million
Num Shares 12.4 Million
EPS -0.36
Price-to-Earnings (P/E) Ratio -4.75
Price-to-Sales 4.01
Price-to-Book 26.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.89
Resistance 3 (R3) 1.88 1.80 1.86
Resistance 2 (R2) 1.80 1.76 1.81 1.85
Resistance 1 (R1) 1.76 1.73 1.78 1.77 1.84
Pivot Point 1.68 1.68 1.70 1.69 1.68
Support 1 (S1) 1.64 1.64 1.66 1.65 1.58
Support 2 (S2) 1.56 1.61 1.57 1.57
Support 3 (S3) 1.52 1.56 1.56
Support 4 (S4) 1.53